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Descriptor: 10.12 Pneumonia: Bacterial Infections 
Word count: 3118 
At a Glance Commentary: 
Scientific Knowledge on the Subject: 
A correct interpretation of the inflammatory response at diagnosis of community-acquired 
pneumonia (CAP) can improve initial assessment of severity, management and prediction of 
outcome. So far, evaluation of initial inflammatory cytokines and biomarkers is performed 
without considering time since onset of symptoms, which could modify systemic biomarkers 
levels depending on its own kinetics and the phase of infection.  
What This Study Adds to the Field: 
The present study demonstrates that time elapsed since symptoms onset to CAP diagnosis 
influences the systemic inflammatory profile differently for each cytokine. Patients with 3 or 
more days since symptoms onset showed lower levels of procalcitonin (PCT), interleukin 
(IL)-6 and IL-8, whereas those with less than 3 days had lower levels of C-reactive protein 
(CRP), even in those with sepsis. These findings provide new insight about the most useful 
window period for biomarker analyses: PCT within the first 48 h since onset of symptoms 
and CRP, IL-6 and IL-8 for those with 3 or more days. Onset of CAP symptoms should be 
considered at diagnosis to avoid underestimating the inflammatory response and for the 
future design of randomized clinical trials.  
This article has an online data supplement, which is accessible from the online table of 
contents at www.atsjournals.org. 
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ABSTRACT 
Rationale. Assessment of the inflammatory response can help decision-making process 
when diagnosing community-acquired pneumonia (CAP), but there is a lack of information 
about the influence of time since onset of symptoms. We studied the impact of the number 
of days since onset of symptoms on inflammatory cytokines and biomarkers concentrations 
at CAP diagnosis in hospitalized patients. 
Methods. We performed a secondary analysis in two prospective cohorts including 541 
patients in the derivation cohort and 422 in the validation cohort. The time since onset of 
symptoms was self-reported and patients were classified as early presenters (<3 days) and 
non-early presenters. Biomarkers (C-reactive protein and procalcitonin (PCT) in both 
cohorts) and cytokines in the derivation cohort (interleukins 1, 6, 8, 10, and tumor necrosis 
factor-alpha) were measured within 24 hours of hospital admission. 
Results. In early presenters, C-reactive protein was significantly lower whereas 
procalcitonin, interleukin-6 and 8 were higher. Non-early presenters showed significantly 
lower procalcitonin, interleukin-6, and interleukin-8 levels. In the validation cohort, CRP and 
PCT exhibited identical pattern: CRP levels were 36.4% greater in patients with ≥3 days 
compared to those with <3 days in the derivation cohort and 38.2% in the validation cohort. 
PCT levels were 40% lower in patients with ≥3 days in the derivation cohort and 56% in the 
validation cohort. 
Conclusion. Time since symptoms onset modifies the systemic inflammatory profile at CAP 
diagnosis. That information has relevant clinical implications for management and it should 
taken into account in the design of future clinical trials. 
Word count: 247 
Keywords: pneumonia, inflammation, symptoms onset  
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INTRODUCTION 
Community-acquired pneumonia (CAP) remains an important infectious disease with 
a significant global burden, and is considered a major cause of sepsis worldwide (1, 2). 
Appropriate initial severity assessment and management at the emergency room (ER) can 
improve the prognosis, result in fewer complications, and reduce costs (3, 4).  
In recent decades, physicians have made initial assessments of pneumonia based on 
symptoms, physical examination, and complementary data (e.g., x-rays or laboratory tests) 
supported by prognostic scales like the Pneumonia Severity Index, CURB65 (5,6), or the 
more recent quick Sequential Organ Failure Assessment (qSOFA) (7). Over time, these scales 
have been combined with biomarkers and inflammatory cytokines to improve the decision-
making process and to predict poor outcomes (8, 9). In the diagnostic process of lower 
respiratory tract infections and in sepsis, procalcitonin (PCT) levels have been used to decide 
both antibiotic initiation and its duration (10–13). Moreover, treatment may differ based on 
initial inflammatory biomarker levels, as corticosteroid treatment was found to reduce 
treatment failure in patients with high initial CRP levels (14). 
The interest in knowing the different patterns of inflammation and their related 
factors has led to a better understanding of the immunopathogenic process that occurs in 
CAP (15–17). The natural course of the infection and its systemic inflammatory pattern prior 
to diagnosis is rather unknown, although presumably it can differ depending on the 
duration of the infection and the distinct kinetics of inflammatory cytokine and biomarkers. 
Our hypothesis was that time since onset of symptoms influences the systemic 
concentrations of inflammatory cytokines and biomarkers levels at CAP diagnosis, mainly 
during the first hours when bacterial growth is taking place and the host is mounting the 
inflammatory response. So far, there is a lack of published data about that aspect that we 
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considered key for interpreting the initial inflammatory pattern in CAP. 
Accordingly, we aimed to evaluate the influence of time since onset of symptoms on 
the initial levels of inflammatory cytokines and biomarkers at CAP diagnosis in hospitalized 
patients. Additionally, our findings were evaluated in a different cohort with data of 
biomarkers at CAP diagnosis. Some of the results of these studies have been previously 
reported in the form of an abstract (18, 19). 
 
PATIENTS AND METHODS 
Design and Study Population 
The study involved secondary analyses of data from two prospective longitudinal 
cohorts. First cohort, or derivation cohort, was recruited at two tertiary-care university 
hospitals in Spain from 2004 to 2006 and from 2012 to 2015 (Hospital La Fe, Valencia; 
Hospital Clínic, Barcelona). Second cohort, or validation cohort, was obtained from a 
database of two different tertiary-care university hospitals in Spain from 2012 to 2015 
(Hospital de Galdakao, Galdakao; Hospital de Mataró, Mataró). The local ethics committees 
approved the study, and either patients or their closest relatives provided written informed 
consent. The study was conducted in accordance with the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) guidelines (20). 
CAP was diagnosed if new acute respiratory symptoms, signs, and compatible 
infiltrate(s) on chest x-ray were present. Exclusion criteria were age <18 years, other active 
infection, admission within prior 15 days, nursing-home residence, and if 
immunocompromised (e.g., transplant recipients, patients with malignancies, HIV+ patients, 
or treatment with ≥20 mg/day of prednisone or equivalent for >14 days). We also excluded 
patients with chronic liver disease because C-reactive protein (CRP) is mainly produced in 
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hepatocytes after stimulation by some interleukins (IL) (21, 22). 
Data Collection and Definitions 
We collected data on demographic characteristics and comorbidities (i.e., diabetes 
mellitus, respiratory, heart, liver, neurological, and renal diseases). The severity of disease at 
presentation was assessed with the Pneumonia Severity Index (PSI) and sepsis was defined 
according to the updated clinical criteria reported by the Sepsis-3 Task Force (5, 23). 
Antibiotic treatment before CAP diagnosis in the current episode was recorded. 
The time, measured in days since the onset of CAP symptoms and/or signs until 
diagnosis at the ER, was self-reported by patients themselves or by close relatives during 
clinical interview. Any respiratory symptoms and/or signs (i.e., chest pain, cough, 
expectoration, dyspnea, chills, and temperature ≥37.8ºC) related to the acute process were 
considered. According to symptoms onset, patients were divided into two groups: “early 
presenters” if time was <3 days and “non-early presenters” if ≥3 days. That threshold was 
selected taking into account that during the first 48 hours bacterial growth is rising and 
systemic inflammation is escalating as observed in pneumonia animal models (24–26). 
Outcomes evaluated were length of stay and mortality during hospitalization and at 
30 days following hospital admission. 
Microbiological Tests 
The following microbiological studies were carried out: paired blood cultures, urinary 
antigens for Legionella pneumophila and Streptococcus pneumoniae, sputum Gram stain (if 
<10 epithelial cells and >25 leukocytes per field; magnification ×100) and culture, paired 
serological studies for Chlamydophila pneumoniae, Mycoplasma pneumoniae, Coxiella 
burnetii, and Legionella pneumophila. Invasive samples by bronchoscopy and/or 
pleurocentesis were obtained if required by the attending physician. 
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Study of Biomarkers and Cytokines 
 Venous blood samples were obtained within the first 24 hours of hospital admission 
and processed to acquire serum, which was stored at -80 °C until analysis. Determination of 
cytokines was made using an enzyme immunoassay (BioSource) according to the 
manufacturer’s instructions. Cytokines were only analyzed in the derivation cohort. The 
cytokines of interest were IL-1, IL-6, IL-8, IL-10, and tumor necrosis factor-alpha (TNF-α). 
Procalcitonin (PCT) levels were determined using an immunoluminometric technique 
(Liason Brahms PCT) with a detection limit of 0.03 ng/mL. C-reactive protein (CRP) was 
detected using an immunoturbidimetric test (Bayer diagnostics) with a detection limit of 
0.15 mg/L. In the validation cohort, PCT levels were determined using an 
electrochemiluminiscence immunoassay in a Cobas 6000e autoanalyzer (Roche Diagnostics) 
with an analytical sensitivity of 0.02 ng/mL and coefficients of variation, obtained in routine 
(one run daily), of 3.26% (0.51 ng/mL) and 4.72% (9.48 ng/mL). CRP levels were measured 
using an inmunoturbidimetric method in a Cobas 6000c autoanalyzer (Roche Diagnostics) 
with an analytical sensitivity of 1 mg/L and coefficients of variation obtained in routine (one 
run daily) of 4.85% (9.33 mg/L) and 5.61% (40.63 mg/L). 
Statistical Analysis 
Statistical analyses were performed using IBM SPSS 20.0 software (SPSS, Chicago, Ill). 
Patients were grouped and compared with regard to classification as early or non-early 
presenters. Baseline characteristics, comorbidity, previous antibiotic treatment, prognostic 
scales, severity (i.e. PSI), and the presence of sepsis were analyzed and compared. 
Categorical variables were presented as n (%) and compared with the χ2 test, while 
continuous variables were presented as medians and interquartile ranges (IQR) and 
analyzed with the Mann–Whitney U test. Values of p < 0.05 were considered significant. 
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Radar plots were built to illustrate the concentration of cytokines and biomarkers according 
to time since onset of symptoms.  
 
RESULTS 
Patients’ Baseline Characteristics 
We included 584 patients in the derivation cohort and 422 in the validation cohort 
(Figure 1). The median duration since onset of symptoms until CAP diagnosis in the ER was 5 
days in both cohorts (IQR 3–7 days). 122 patients (22.6%) in the derivation cohort and 82 
(20.6%) in the validation cohort had attended the ER within the first 48 hours of symptoms 
(early presenters). Early presenters were older, had more comorbidities, and greater initial 
CAP severity in both cohorts. By contrast, non-early presenters had more often received 
antibiotic treatment before admission. The most notable differences between the two 
cohorts were pneumococcal vaccination, previous antibiotic treatment and change in 
mental status (less frequent in the validation cohort). Longer length of stay was found in 
early presenters in the derivation cohort but not in the validation cohort. No significant 
differences in other outcomes were found when comparing the two cohorts (Table 1). 
 
Biomarkers and Cytokines Related to Time since Onset of Symptoms 
Derivation cohort. Biomarker and cytokine levels are depicted in Figure 2 according 
to duration of symptoms at CAP diagnosis in patients with or without previous antibiotic 
treatment. No significant differences were found for any of the biomarkers or cytokines 
with regard to previous antibiotic treatment (see Table E1 in the online supplement). CRP 
levels were highest in patients with ≥3 days of symptoms, whereas PCT, IL-6, and IL-8 
showed higher levels in patients with <3 days of symptoms (Table 2). Early presenters had 
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significantly lower CRP concentrations and higher PCT, IL-6, and IL-8 concentrations. Figure 
3 shows all biomarkers and cytokines expressed in deciles of concentrations in the 
derivation cohort in early and non-early presenters. 
Validation cohort. Early presenters also showed significant lower levels of CRP in 
comparison to non-early presenters (Table 2). The median levels of CRP were 38.2% greater 
in patients with ≥3 days compared to those with <3 days, and 36.4% in the derivation 
cohort. By contrast, higher levels of PCT were found in those patients with early 
presentation. The median levels of PCT were 40% lower in patients with ≥3 days in 
comparison with those with <3 days in the derivation cohort and 56% in the validation 
cohort. 
 
Biomarkers and Cytokines by Initial Severity: PSI and Sepsis 
Derivation cohort. When we analyzed data according to severity, in patients with 
mild disease (PSI I-III) PCT and IL-6 levels were lower in those with longer duration of 
symptoms; by comparison, patients with more severe disease (PSI IV-V) and <3 days of 
symptoms had lower CRP levels (Table 3). Patients with sepsis showed significantly higher 
levels of CRP compared to those without sepsis. There were lower levels of CRP in patients 
with <3 days since onset of symptoms when compared to those with ≥3 days, irrespective of 
the presence of sepsis (Figure 4a). PCT levels in early presenters with sepsis were higher 
compared to those without sepsis in the derivation cohort (p<0.05) (Figure 4b). 
Validation cohort. In patients with mild disease (PSI I-III), significantly lower levels of 
CRP were found in early presenters, with a trend, that did not reach statistical significance, 
in those with PSI IV-V. No significant differences were found in PCT (Table 3). In sepsis, CRP 
levels showed a trend to lower levels in early presenters without reaching statistical 
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significance (16.5 [8.5-26.9] vs 21.4 [10.6-30.5] mg/L, p: 0.092) (Figure 4a). With respect to 
PCT levels, early presenters with sepsis showed a trend toward higher levels without 
reaching statistical significance (2.75 [0.27-5.26] vs 1.3 [0.27-5.26] ng/mL, p: 0.100) (Figure 
4b).  
  
DISCUSSION 
The main findings of our study are as follows: first, we showed that the inflammatory 
response at the time of CAP diagnosis was influenced by the time since onset of symptoms. 
Second, we showed that the CRP level was significantly lower in patients presenting <3 days 
since onset of symptoms, while PCT, IL-6, and IL-8 were already elevated. Third, we showed 
that PCT, IL-6, and IL-8 were significantly reduced after 3 days of symptoms, but that CRP 
was still raised; these findings were confirmed for PCT and CRP in the validation cohort. The 
inflammatory patterns were maintained in patients with sepsis in the derivation cohort and 
a similar trend was observed in the validation cohort. Based on these results, we believe 
that the initial biomarker levels at CAP diagnosis should be interpreted considering the 
number of days since the onset of CAP symptoms. 
In this study, we have demonstrated that the inflammatory systemic response differs 
at the time of CAP diagnosis, specifically when many clinical decisions are made, depending 
on the number of days since symptoms onset. In the derivation cohort, the median time 
since symptom onset to CAP diagnosis was 5 days, with 22.6% of patients diagnosed within 
the first 48 hours, similar to prior publications (27), very similar to the percentage in the 
validation cohort. Patients who had more comorbidities, higher initial severity (PSI IV-V), 
and were older tended to present sooner at the ER in both cohorts. This may reflect their 
greater awareness of respiratory symptoms and the risk of poor evolution.    
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The inflammatory profile in non-early presenters was characterized by lower 
expressions of PCT and proinflammatory cytokines, apart from CRP, compared to those 
patients with 3 days or less from onset of symptoms, probably because the more intense 
infection phase has ended. Our findings were corroborated in the validation cohort, even 
though the biomarker analysis methods were not identical. Our data could be explained by 
a depletion and exhaustion of biomarker production over time in the process of fighting 
microorganisms. To our knowledge, there are no comparable published data in patients, 
apart from the study by Calbo et al. who performed a small study in 32 adults with 
pneumococcal CAP, splitting them on early (<48h) or late-comers (25). Dallaire et al., in a 
mouse model of pneumococcal pneumonia, determined that a plateau of bacterial growth 
was reached at 36 hours and that of inflammatory mediators at 84 hours post-infection, 
followed by a posterior bacterial load drop after 92 hours (24). Reyes et al., in a baboon 
animal pneumonia model, described that after a challenge with Streptococcus pneumoniae 
there is a rapid (24 hours) increase in serum proinflammatory cytokines and chemokines, 
which remain raised during 5-6 days, with a later rapid decline after antibiotic treatment 
(26, 28). 
The systemic inflammatory pattern in patients diagnosed within <3 days of 
symptoms showed a greater inflammatory expression of IL-6, IL-8, and PCT, supporting the 
idea of a more robust early response during the first days except for CRP, which has slower 
kinetics (29). A delay of 48 hours in the peak levels of CRP with regard to IL-6 (main inducer 
of CRP production in hepatocytes) has been documented in animal models and healthy 
volunteers after IL-6 stimulation (30, 31). A similar profile was confirmed in the validation 
cohort with regard to CRP and PCT, despite the fact that PCT levels were slightly higher in 
that cohort compared to the derivation cohort. In fact, non-early presenters showed CRP 
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levels 36.4% higher then the early presenters in the derivation cohort and 38.2% in the 
validation cohort. On the other hand, non early-presenters had levels of PCT 40% and 56% 
lower in the derivation and validation cohort respectively. After microorganisms enter the 
lung there is an early innate immune response provoking systemic inflammation in 24-48 
hours. Martínez-Olondris et al., in a piglet pneumonia model with methicillin-resistant 
Staphylococcus aureus, detected at 24 hours of inoculum an increase in systemic levels of IL-
6, IL-8 and TNF-α (32). CRP behaved differently, with levels increasing until day 3 and 
remaining sustained until day 7, regardless of the use of prior antibiotics. Calbo et al. 
reported similar CRP results in early presenters (>48 hours), concluding that they could be 
related to bacterial growth, as reported in animal models of pneumonia (24, 25). In the 
present study, we observed maximum CRP levels and a turning point on day 3. 
The inflammatory pattern according to time since onset of CAP symptoms was also 
observed in the subset of patients with higher initial severities (PSI IV-V) in the derivation 
cohort. We observed the same trend in PSI IV-V patients, although without reaching 
statistical significant difference, in the validation cohort, probably due to a beta error. On 
the other hand, in sepsis, CRP levels were significantly lower in early presenters compared 
to non-early presenters, who had levels 40.3% higher in the derivation cohort. In contrast, 
PCT and IL-6 or IL-8 levels were significantly higher in early presenters. A similar trend was 
observed in patients with sepsis from the validation cohort with an increase in CRP of 30.3% 
and a decrease in PCT of 53.8% in non-early presenters compared to the early presenters. 
The clinical impact of assessing inflammation and initial severity through biomarkers 
(mainly PCT and CRP) and cytokines has been investigated for the management of 
respiratory infections (33, 34). Our findings point out to the importance of that neglected 
factor to interpret biomarkers levels at CAP diagnosis. We highlight the possibility of 
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underestimating the inflammatory response and, consequently, misclassifying disease 
severity depending on the biomarker or cytokine used. In a randomized clinical trial, Torres 
et al. reported that corticosteroid treatment added to antibiotics in CAP patients with high 
initial inflammation (CRP >15 mg/L) reduced treatment failure (14). Nevertheless, we can 
speculate that in patients diagnosed within the first 48 hours since onset of symptoms, CRP 
could underestimate inflammatory response because that biomarker is still in an increasing 
phase. Given our observations, duration of symptoms should also be considered in the 
design of future clinical trials evaluating the inflammatory response. 
For the daily clinical practice at CAP diagnosis, we propose a simple useful 
recommendation: PCT (or IL-6, IL-8) is superior when assessing disease severity in patients 
with symptoms for <3 days, whereas CRP is a better choice in patients with symptoms for ≥3 
days. Noteworthy, cytokines and biomarkers levels found at diagnosis reflect the highest 
inflammatory profile reached during the CAP episode, because after antibiotic treatment 
their levels will rapidly – IL-6, IL-10, PCT– or more slowly –IL-8– decline (35). 
Our study has some limitations. Notably, the time since symptom onset was self-
reported (or reported by close relatives) and dependent on the subjective perception of 
symptoms, and will have been influenced by demographic, cultural, socioeconomic, 
tolerance, and another external factors (36). However, in this kind of clinical research there 
is no objective way to determine the exact onset of CAP infection, opposite to what occurs 
for other causes of sepsis (e.g., wounds) (37). In addition, we have no data about the first 
symptom to appear. In the case of influenza, oseltamivir is more effective during the first 
days after the onset of fever. It would be interesting to analyze these data in a prospective 
study (38). Another limitation is that microbiological testing was not systematically done to 
diagnose viruses. Indeed, it is known that the inflammatory response to viral infections, 
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alone or combined with bacteria, has a different pattern to that shown for bacterial 
infections (39, 40). Our validation cohort has no cytokine data although we consider that for 
clinical purposes data on CRP and PCT are easily available in most hospitals. 
 
Conclusions 
In summary, these results highlight the influence of time since onset of symptoms 
until presentation on the interpretation of inflammatory markers in CAP. Patients who 
present ≥3 days after onset of symptoms may have decreased levels of some biomarkers 
(e.g., PCT, IL-6, and IL-8), whereas in those diagnosed within the first 48h the inflammatory 
response measured by CRP is still in an increasing phase, even in patients with more severe 
disease. Our findings have easy and rapid clinical translation at CAP diagnosis to avoid 
underestimation of host response: PCT (and/or IL-6, IL-8) investigation is recommended in 
patients with ≤48 hours since onset of symptom, while CRP is better in patients with 3 days 
or more. Thus, we conclude that the inflammatory response must be interpreted taking into 
account the duration of symptoms in clinical assessment at CAP diagnosis and also when 
designing and conducting randomized clinical trials. 
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Table 1. Baseline characteristics according to time since onset of symptoms 
 Derivation Cohort Validation Cohort 
 
< 3 days 
122 (22.6) 
≥ 3 days 
419 (77.4) 
p-value 
< 3 days 
82 (20.6) 
≥ 3 days 
316 (79.4) 
p-value 
Demographic       
Age (years) 75 (64-81) 69 (55-78) <0.001 75 (64-84) 67 (51-79) 0.001 
Men 93 (76.2) 268 (64) 0.011 54 (65.9) 196 (62) 0.523 
Pneumococcal vaccine 16 (13.1) 42 (10) 0.331 1 (1.2) 14 (4.4) 0.060 
Influenza vaccine 56 (45.9) 159 (37.9) 0.114 32 (39) 117 (37) 0.149 
Alcohol abuse 3 (3.8) 6 (2.4) 0.500 5 (6.1) 12 (3.8) 0.891 
Current smokers 16 (20) 64 (25.1) 0.351 14 (17.1) 56 (17.7) 0.351 
Comorbidities and 
treatments 
      
Respiratory disease 51 (42.5) 143 (34.4) 0.103 22 (26.8) 75 (23.7) 0.561 
Neurological disease 33 (27) 56 (13.5) <0.001 17 (21) 47 (14.9) 0.186 
Heart failure 31 (25.4) 59 (14.1) 0.003 22 (26.8) 69 (21.8) 0.337 
Renal disease 12 (9.8) 34 (8.1) 0.549 13 (15.9) 26 (8.3) 0.039 
Diabetes Mellitus 36 (29.5) 84 (20) 0.027 13 (15.9) 58 (18.4) 0.598 
Previous pneumonia 47 (38.5) 100 (23.9) 0.001 20 (24.7) 32 (10.3) 0.001 
Inhaled corticosteroids 29 (23.8) 89 (21.2) 0.552 22 (26.8) 60 (19) 0.118 
Previous antibiotic 
treatment 
24 (19.7) 162 (38.7) <0.001 9 (11) 64 (20.3) 0.053 
Symptoms       
Fever 93 (76.2) 326 (77.8) 0.714 53 (72.6) 212 (70.7) 0.744 
Shivering 85 (69.7) 276 (66.8) 0.556 39 (52.7) 117 (39.9) 0.047 
Cough 84 (68.9) 348 (83.7) <0.001 48 (62.3) 250 (81.7) <0.001 
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Expectoration 42 (52.5) 148 (58.3) 0.364 33 (47.1) 169 (57.7) 0.111 
Dyspnea 76 (62.3) 265 (63.4) 0.824 36 (46.8) 129 (42.9) 0.538 
Chest pain 44 (36.4) 176 (42.4) 0.234 25 (34.7) 83 (29) 0.346 
Change in mental status 26 (21.5) 44 (10.7) 0.002 6 (8.7) 13 (4.6) 0.181 
Digestive symptoms 25 (20.5) 86 (20.6) 0.984 5 (7.2) 31 (11) 0.354 
Initial severity       
Sepsis 69 (61.6) 211 (54.2) 0.167 44 (53.7) 162 (51.3) 0.699 
Pneumonia Severity 
Index class 
  
0.002 
  
0.037 
I 9 (7.4) 58 (13.8) 8 (9.8) 63 (19.9) 
II 18 (14.8) 87 (20.8) 10 (12.2) 47 (14.9) 
III 22 (18) 109 (26) 18 (22) 77 (24.4) 
IV 52 (42.6) 125 (29.8) 28 (34.1) 92 (29.1) 
V 21 (17.2) 40 (9.5) 18 (22) 34 (10.8) 
Microbiology     
Etiologic diagnosis 52 (44.1) 185 (44.5) 0.938 23 (28) 101 (32.1) 0.119 
Streptococcus 
pneumoniae 
31 (25.4) 79 (18.9) 0.113 19 (23.8) 75 (23.8) 0.991 
Legionella pneumophila 0 (0) 26 (6.2) 0.005 1 (1.2) 9 (2.8) 0.401 
Atypical bacteria 5 (4.1) 38 (9.1) 0.076 2 (3.1) 4 (1.5) 0.397 
Polymicrobial 9 (7.5) 44 (10.6) 0.323 0 (0) 10 (3.7) 0.110 
Bacteremia 14 (11.5) 31 (7.4) 0.151 9 (15.5) 27 (13.3) 0.666 
Outcomes       
Length of stay (days) 8 (6-10) 7 (5-10) 0.012 4 (3-8) 4 (3-7) 0.912 
In-hospital mortality 4 (3.3) 18 (4.3) 0.617 5 (6.1) 11 (3.2) 0.282 
30 days mortality 6 (4.9) 20 (4.8) 0.948 5 (6.1) 12 (3.8) 0.359 
Data presented as n (%) or median (IQR) 
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Table 2. Biomarkers according to time since onset of symptoms  
 Derivation Cohort Validation Cohort 
 
< 3 days 
N: 122 
≥ 3 days 
N: 419 
p-value 
≤ 3 days 
N: 82 
> 3 days 
N: 316 
p-value 
CRP (mg/L) 13.2 (7.8-23.3) 18 (9.9-27.9) 0.005 13.6 (6.6-23.5) 18.8 (9.2-29.3) 0.006 
PCT (ng/mL) 0.5 (0.1-3.4) 0.3 (0.1-1.5) 0.023 0.9 (0.2-5) 0.4 (0.1-2.3) 0.028 
TNF-α (pg/mL) 16 (4-32) 14 (3.8-30) 0.439 – – – 
IL-1 (pg/mL) 4 (0.5-10) 3 (0.5-16) 0.595 – – – 
IL-6 (pg/mL) 97 (22-238.8) 53.5 (17-162) 0.012 – – – 
IL-8 (pg/mL) 15 (7-28) 11 (2.7-20.1) 0.001 – – – 
IL-10 (pg/mL) 2.6 (1-11) 2.6 (0-11) 0.670 – – – 
Data presented as median (IQR) 
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Table 3. Biomarkers according to time since onset of symptoms and initial severity 
 Derivation Cohort Validation Cohort 
 
< 3 days 
N: 122 
≥ 3 days 
N: 419 
p-value 
< 3 days 
N: 82 
≥ 3 days 
N: 316 
p-value 
PSI I-III 49 (16.2) 254 (83.8)  36 (16.1) 187 (83.9)  
CRP (mg/L) 16 (7.8-24.3) 17.4 (8.3-27) 0.394 12.7 (6.2-22.7) 19.1 (9.3-30) 0.016 
PCT (ng/mL) 0.3 (0.1-2.1) 0.2 (0.1-0.8) 0.005 0.4 (0.1-1.1) 0.3 (0.1-1.3) 0.562 
TNF-α (pg/mL) 14 (3.8-23) 12 (3.8-24.5) 0.985 – – – 
IL-1 (pg/mL) 2 (0.5-12) 2.9 (0.5-12) 0.762 – – – 
IL-6 (pg/mL) 60 (18-153.2) 36.6 (14-133) 0.186 – – – 
IL-8 (pg/mL) 13 (6-18) 8 (2.7-15) 0.046 – – – 
IL-10 (pg/mL) 2.2 (2-7) 2.2 (0-9.3) 0.809 – – – 
PSI IV-V 73 (30.7) 165 (69.3)  46 (26.7) 126 (73.3)  
CRP (mg/L) 13 (6.6-22.4) 19 (12-30) 0.001 16.1 (7.3-23.5) 18.5 (8.5-28.7) 0.133 
PCT (ng/mL) 0.7 (0.1-4.6) 0.6 (0.2-2.9) 0.851 2.8 (0.3-7.2) 1.2 (0.2-4.9) 0.081 
TNF-α (pg/mL) 19.5 (6-37) 18 (3.8-44) 0.832 – – – 
IL-1 (pg/mL) 4 (1.4-10) 4 (0.5-18) 0.782 – – – 
IL-6 (pg/mL) 122.5 (35-391) 82.3 (23-286.7) 0.274 – – – 
IL-8 (pg/mL) 18.5 (8-35) 14 (4-31.6) 0.142 – – – 
IL-10 (pg/mL) 3 (0-12) 3 (0-15.1) 0.914 – – – 
Data presented as n (%) or median (IQR) 
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Figure Legends: 
Figure 1. Study flowchart. A: Derivation cohort; B: Validation cohort. 
Figure 2. Biomarker concentrations (expressed as medians) according to time since onset of 
symptoms and previous antibiotic. 
Figure 3. Radar plot of biomarkers according to time since onset of symptoms. Numbers 
express the deciles of biomarker concentrations. A: <3 days; B: ≥3 days. 
Figure 4. Biomarker concentrations (expressed as medians) according to time since onset of 
symptoms and sepsis. NS: Not significant; A: C-reactive protein; B: procalcitonin. 
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